Various MDSC-targeting strategies have been evaluated in murine models of uterine cervical and endometrial cancers (Table 2), such as anti-Gr-1 antibody [22,29,31], anti-IL-6 antibody [32], COX-2 inhibitor [29], STAT3 inhibition [32], and splenectomy [21,28]. The gene discussed is IL6; the disease is endometrial cancer.